These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

190 related items for PubMed ID: 11162510

  • 1. Biological effects of anti-ErbB2 single chain antibodies selected for internalizing function.
    Neve RM, Nielsen UB, Kirpotin DB, Poul MA, Marks JD, Benz CC.
    Biochem Biophys Res Commun; 2001 Jan 12; 280(1):274-9. PubMed ID: 11162510
    [Abstract] [Full Text] [Related]

  • 2. Epitope mapping and structural analysis of an anti-ErbB2 antibody A21: Molecular basis for tumor inhibitory mechanism.
    Hu S, Zhu Z, Li L, Chang L, Li W, Cheng L, Teng M, Liu J.
    Proteins; 2008 Feb 15; 70(3):938-49. PubMed ID: 17847085
    [Abstract] [Full Text] [Related]

  • 3. Selection of tumor-specific internalizing human antibodies from phage libraries.
    Poul MA, Becerril B, Nielsen UB, Morisson P, Marks JD.
    J Mol Biol; 2000 Sep 01; 301(5):1149-61. PubMed ID: 10966812
    [Abstract] [Full Text] [Related]

  • 4. Targeting of bivalent anti-ErbB2 diabody antibody fragments to tumor cells is independent of the intrinsic antibody affinity.
    Nielsen UB, Adams GP, Weiner LM, Marks JD.
    Cancer Res; 2000 Nov 15; 60(22):6434-40. PubMed ID: 11103810
    [Abstract] [Full Text] [Related]

  • 5. A chimeric humanized single-chain antibody against the type I insulin-like growth factor (IGF) receptor renders breast cancer cells refractory to the mitogenic effects of IGF-I.
    Sachdev D, Li SL, Hartell JS, Fujita-Yamaguchi Y, Miller JS, Yee D.
    Cancer Res; 2003 Feb 01; 63(3):627-35. PubMed ID: 12566306
    [Abstract] [Full Text] [Related]

  • 6. Toward selection of internalizing antibodies from phage libraries.
    Becerril B, Poul MA, Marks JD.
    Biochem Biophys Res Commun; 1999 Feb 16; 255(2):386-93. PubMed ID: 10049718
    [Abstract] [Full Text] [Related]

  • 7. Differential binding of human immunoagents and Herceptin to the ErbB2 receptor.
    Troise F, Cafaro V, Giancola C, D'Alessio G, De Lorenzo C.
    FEBS J; 2008 Oct 16; 275(20):4967-79. PubMed ID: 18795950
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Biological properties of a human compact anti-ErbB2 antibody.
    De Lorenzo C, Cozzolino R, Carpentieri A, Pucci P, Laccetti P, D'Alessio G.
    Carcinogenesis; 2005 Nov 16; 26(11):1890-5. PubMed ID: 15930029
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Epidermal growth factor receptor coexpression modulates susceptibility to Herceptin in HER2/neu overexpressing breast cancer cells via specific erbB-receptor interaction and activation.
    Diermeier S, Horváth G, Knuechel-Clarke R, Hofstaedter F, Szöllosi J, Brockhoff G.
    Exp Cell Res; 2005 Apr 01; 304(2):604-19. PubMed ID: 15748904
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effective suppression of breast tumor growth by an anti-EGFR/ErbB2 bispecific antibody.
    Wang S, Chen C, Meng Y, Hu S, Zheng L, Song J, Zhang D, Li B, Guo Y.
    Cancer Lett; 2012 Dec 28; 325(2):214-9. PubMed ID: 22789781
    [Abstract] [Full Text] [Related]

  • 14. PC cell-derived growth factor stimulates proliferation and confers Trastuzumab resistance to Her-2-overexpressing breast cancer cells.
    Kim WE, Serrero G.
    Clin Cancer Res; 2006 Jul 15; 12(14 Pt 1):4192-9. PubMed ID: 16857791
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16. Activation of ErbB2 by overexpression or by transmembrane neuregulin results in differential signaling and sensitivity to herceptin.
    Yuste L, Montero JC, Esparís-Ogando A, Pandiella A.
    Cancer Res; 2005 Aug 01; 65(15):6801-10. PubMed ID: 16061662
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.